BioMark Diagnostics【BUX】銘柄情報

BioMark Diagnostics Inc (BUX) 銘柄情報

個人投資家向けのプロ仕様のツール。

プレミアム

通貨

0.54

( - )

買値

0.53

売値

0.54

出来高

1,500

0.54 日の範囲 0.54

0.27 52 週間の範囲 0.64

時価総額

57.501M

前日終値

0.54

始値

0.54

時刻

500

0.54

最終取引時間

財務取引量

VWAP

平均取引量 (3 か月)

$ 1,177

発行済株式数

106,483,435

配当利回り

PER

-31.54

1 株当たり利益 (EPS)

-0.02

歳入

91.77k

純利益

-1.7M

Biomark Diagnostics Inc. develops early-stage cancer diagnostic technology platform to detect and treat cancer. The company invests in and develops a liquid biopsy metabolic panel assay for the early-stage diagnosis of lung cancer, as well as glioblastoma (GBM), breast cancer, and head and neck canc... Biomark Diagnostics Inc. develops early-stage cancer diagnostic technology platform to detect and treat cancer. The company invests in and develops a liquid biopsy metabolic panel assay for the early-stage diagnosis of lung cancer, as well as glioblastoma (GBM), breast cancer, and head and neck cancer. It is also developing liquid biopsy tests for various cancer types, including glioblastoma, gastrointestinal, prostate, head, neck cancers. The company was incorporated in 2014 and is headquartered in Richmond, Canada. 詳細を表示

セクター

Healthcare

業界

Medical Diagnostics & Screening

ウェブサイト

www.biomarkdiagnostics.com

本社

Richmond, Canada

設立

2026

BioMark Diagnostics Inc is listed in the Healthcare sector of the Canadian Securities Exchange with ticker BUX. The last closing price for BioMark Diagnostics was $0.54. Over the last year, BioMark Diagnostics shares have traded in a share price range of $ 0.27 to $ 0.64.

BioMark Diagnostics currently has 106,483,435 shares in issue. The market capitalisation of BioMark Diagnostics is $57.50 million. BioMark Diagnostics has a price to earnings ratio (PE ratio) of -31.54.

BioMark Diagnostics Secures Landmark Canadian and European Patent Allowances for Early-Stage Lung Cancer Blood Test

BioMark prepares to launch its breakthrough liquid biopsy powered by a newly patented algorithm validated in...

BioMark Secures Broad U.S. Patent for Urine-Based Lung Cancer Screening, Expanding Differentiated Liquid Biopsy Testing Platform

New patent expands globally protected IP estate beyond blood into alternative biofluids, positioning the...

BioMark Diagnostics to Present Liquid Biopsy Platform at the Canadian Thoracic Society Research Forum

BioMark Comprehensive Metabolomics Assay Selected as Top Canadian Innovation for the CTS Beaver Den Innovation...

BioMark Diagnostics Announces Publication of Peer-Reviewed Validation of Machine Learning Models for Lung Cancer Detection in Frontiers in Oncology

Advancing Superior Accuracy in Early Lung Cancer Detection Using Selective Metabolic Pathways and Data...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0.54	0.55	0.48	6253	0.54040384	CS
4	-0.04	-6.89655172414	0.58	0.61	0.48	6921	0.55526884	CS
12	-0.04	-6.89655172414	0.58	0.61	0.48	3904	0.56751921	CS
26	0.06	12.5	0.48	0.64	0.45	7311	0.54446181	CS
52	0.195	56.5217391304	0.345	0.64	0.27	12232	0.42400469	CS
156	0.24	80	0.3	0.64	0.17	13086	0.30880469	CS
260	0.3	125	0.24	0.64	0.15	15758	0.26931556	CS